Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LYL 273

Next Previous
Drug Profile

LYL 273

Alternative Names: Anti- colorectal cancer specific protein (CRCSP) CAR-T cells; Anti- colorectal coupledCAR CAR-T cell therapeutics - Innovative Cellular Therapeutics; Anti-GCC CAR T cells - Innovative Cellular Therapeutics; CRCSP CAR-T cells; GCC19-CART; ICTCAR-CRC; LYL-273

Latest Information Update: 29 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovative Cellular Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Colorectal cancer

Most Recent Events

  • 10 Nov 2025 LYL 273 licensed to Lyell Immunopharma in worldwide (except China, Hong Kong, Macau and Taiwan)
  • 10 Nov 2025 Efficacy and adverse events data from phase I clinical trials in Colorectal cancer released by Lyell Immunopharma
  • 03 Sep 2025 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Second-line therapy or greater) is still underway in USA (IV) (NCT05319314) ( Innovative Cellular Therapeutics pipeline, September 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top